Compare GME & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GME | BMRN |
|---|---|---|
| Founded | 1996 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronics Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1B | 12.3B |
| IPO Year | 2005 | 1999 |
| Metric | GME | BMRN |
|---|---|---|
| Price | $25.23 | $56.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 28 |
| Target Price | N/A | ★ $91.59 |
| AVG Volume (30 Days) | ★ 9.3M | 2.2M |
| Earning Date | 12-08-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 133.33 | N/A |
| EPS | ★ 1.17 | 0.77 |
| Revenue | ★ $3,629,900,000.00 | $1,313,646,000.00 |
| Revenue This Year | $7.49 | $21.42 |
| Revenue Next Year | $11.01 | $14.51 |
| P/E Ratio | ★ $22.49 | $71.70 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $17.79 | $49.26 |
| 52 Week High | $28.30 | $70.98 |
| Indicator | GME | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 52.54 | 44.56 |
| Support Level | $21.23 | $53.89 |
| Resistance Level | $25.34 | $57.88 |
| Average True Range (ATR) | 1.22 | 1.58 |
| MACD | -0.24 | 0.29 |
| Stochastic Oscillator | 26.76 | 65.80 |
GameStop Corp offers games, collectibles, and entertainment products through its stores and ecommerce platforms. Its products include Hardware and accessories offering new and pre-owned gaming platforms from the console manufacturers, Software offering new and pre-owned gaming software for current and certain prior generation consoles and sell a wide range of in-game digital currency, digital downloadable content and full-game downloads, and Collectibles consist of apparel, toys, trading cards, gadgets and other retail products for pop culture and technology enthusiasts and collectibles related services, such as submission services for the authentication and grading of trading cards. The company operates its business in three geographic segments: the United States, Australia, and Europe.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.